Literature DB >> 35768568

Imaging synaptic density in depression.

Sophie E Holmes1, Chadi Abdallah2,3, Irina Esterlis4,5,6.   

Abstract

Major depressive disorder is a prevalent and heterogeneous disorder with treatment resistance in at least 50% of individuals. Most of the initial studies focused on the monoamine system; however, recently other mechanisms have come under investigation. Specific to the current issue, studies show synaptic involvement in depression. Other articles in this issue report on reductions in synaptic density, dendritic spines, boutons and glia associated with stress and depression. Importantly, it appears that some drugs (e.g., ketamine) may lead to rapid synaptic restoration or synaptogenesis. Direct evidence for this comes from preclinical work. However, neuroimaging studies, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), have become useful in assessing these changes in vivo. Here, we describe the use of neuroimaging techniques in the evaluation of synaptic alterations associated with depression in humans, as well as measurement of synaptic restoration after administration of ketamine. Although more research is desired, use of these techniques widen our understanding of depression and move us further along the path to targeted and effective treatment for depression.
© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Entities:  

Year:  2022        PMID: 35768568     DOI: 10.1038/s41386-022-01368-4

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  40 in total

Review 1.  Updated energy budgets for neural computation in the neocortex and cerebellum.

Authors:  Clare Howarth; Padraig Gleeson; David Attwell
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

Review 2.  Current methods and new directions in resting state fMRI.

Authors:  Jackie Yang; Suril Gohel; Behroze Vachha
Journal:  Clin Imaging       Date:  2020-04-12       Impact factor: 1.605

3.  Sequenced Treatment Alternatives to Relieve Depression (STAR*D): lessons learned.

Authors:  Sidney Zisook; Krauz Ganadjian; Christine Moutier; Richard Prather; Sanjai Rao
Journal:  J Clin Psychiatry       Date:  2008-07       Impact factor: 4.384

4.  Evaluating the gray and white matter energy budgets of human brain function.

Authors:  Yuguo Yu; Peter Herman; Douglas L Rothman; Divyansh Agarwal; Fahmeed Hyder
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-07       Impact factor: 6.200

Review 5.  The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders.

Authors:  Gerard Sanacora; Zhen Yan; Maurizio Popoli
Journal:  Nat Rev Neurosci       Date:  2021-12-10       Impact factor: 34.870

6.  Coupling of functional connectivity and regional cerebral blood flow reveals a physiological basis for network hubs of the human brain.

Authors:  Xia Liang; Qihong Zou; Yong He; Yihong Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

7.  Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression.

Authors:  Francisco J Diaz; Danielle James; Sheila Botts; Lorraine Maw; Margaret T Susce; Jose de Leon
Journal:  Bipolar Disord       Date:  2009-03       Impact factor: 6.744

Review 8.  Functional magnetic resonance imaging: a review of methodological aspects and clinical applications.

Authors:  Jürgen Hennig; Oliver Speck; Martin A Koch; Cornelius Weiller
Journal:  J Magn Reson Imaging       Date:  2003-07       Impact factor: 4.813

9.  Graph analysis of resting-state ASL perfusion MRI data: nonlinear correlations among CBF and network metrics.

Authors:  Xiaoyun Liang; Alan Connelly; Fernando Calamante
Journal:  Neuroimage       Date:  2013-11-16       Impact factor: 6.556

10.  Novel approaches to estimate prefrontal synaptic strength in vivo in humans: of relevance to depression, schizophrenia, and ketamine.

Authors:  Chadi G Abdallah; Graeme F Mason
Journal:  Neuropsychopharmacology       Date:  2022-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.